United States· US:50090-6167_ae902cbe-e8b4-42c9-8e85-828d7ca2d2f6
Nabumetone
A nabumetone product containing nabumetone, registered in United States by A-S Medication Solutions. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Nabumetone is registered in 14 of 19 countries.
Countries holding a registration under ATC M01AX01 (nabumetone), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Nabumetone · ATC M01AX01
14 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nabumetone costs, country by country.
Normalised to the WHO defined daily dose (1 g), the median price runs from $0.37 in France to $0.73 in Italy — a ×2.0 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nabumetone · price per daily dose (1 g)
USD · FX 28 Sept 2026
- IT Italy$0.73
- FR France$0.37
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- NABUMETONE
- Manufacturer
- A-S Medication Solutions
- Country
- United States (US)
- ATC code
- M01AX01
- ATC class
- Nabumetone
- Defined daily dose
- 1 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 8
- ndc11500906167030 TABLET in 1 BOTTLE (50090-6167-0)
- ndc11500906167214 TABLET in 1 BOTTLE (50090-6167-2)
- ndc11500906167360 TABLET in 1 BOTTLE (50090-6167-3)
- ndc11500906167420 TABLET in 1 BOTTLE (50090-6167-4)
- ndc1150090-6167-0
- ndc1150090-6167-2
- ndc1150090-6167-3
- ndc1150090-6167-4
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
289 interactions on record for nabumetone.
Graded by severity as the source publishes them — 57 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nabumetone · interactions on record
289 records
- 57 severe
- 142 moderate
- 4 minor
- 86 info
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- DalteparinB01AB04severe
- EnoxaparinB01AB05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nabumetone in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomNabumetone 500mg tabletsTillomed Laboratories Ltd
- FinlandNabumeton Bmm PharmaBMM Pharma AB
- IrelandNabumetone Tillomed 500 mg Film-coated TabletsTillomed Pharma GmbH
- BelgiumGambaran 500 mgViatris Healthcare
- NetherlandsMebutan 1 g, tablettenViatris Healthcare B.V.
- NorwayRelifexViatris AS
- ItalyNABUSER*30 cpr rivestite 1 gPHARMADAY PHARM.Srl UNIPERSONA
- SwedenRelifex 500 mg Filmdragerad tablettEbb Medical AB
Authorised across Europe · EMA
The same active substance is authorised in 18 EEA countries. Names it is sold under:
- Belgium · Gambaran, Nabumeton Tillomed
- Germany · Relifex
- Estonia · Relifex
- Spain · Relif
- France · Nabucom
- United Kingdom (Northern Ireland) · Nabumetone Accord-Uk, Nabumetone Kent Pharma Uk
- Greece · Akratol, Nabuton
- Hungary · Relifex
- Ireland · Nabumetone Tillomed, Relifex
- Iceland · Relifex
- Italy · Nabuser
- Lithuania · Relifex
- Luxembourg · Gambaran
- Latvia · Relifex
- Netherlands · Mebutan, Mebutan Dispers
- Norway · Relifex
- Poland · Nabuton Vp
- Sweden · Relifex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f5e316e5-a416-4ca3-afc2-ee7a9d15e90c GET /v1/drugs/f5e316e5-a416-4ca3-afc2-ee7a9d15e90c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "750",
"substance": "NABUMETONE",
"productndc": "50090-6167",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA078420",
"marketing_category": "ANDA"
}See everything about nabumetone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.